Clinigen announces the acquisition of Ascenian Consulting 

LONDON, UK, 6 June 2024 – Clinigen, the global pharmaceutical services company, today announces the acquisition of Ascenian, a boutique global market access consultancy. Together the combined companies will continue to accelerate access to life-saving treatments, delivering innovative therapies to patients faster. This acquisition signifies a significant milestone in Clinigen’s ongoing evolution towards becoming a premier global provider of high-value services to the pharmaceutical and biotechnology sectors.

Ascenian empowers pharmaceutical and biotech companies to overcome commercialisation challenges with decision planning solutions, from evidence generation to pricing, ensuring patients, caregivers, and healthcare systems have access to health innovations. Ascenian’s proven track record in navigating complex market access hurdles and supporting development of successful commercialisation strategies perfectly complements Clinigen’s existing services. This creates a powerful offering for successful go-to-market strategies ensuring patients benefit from affordable health innovations sooner.

Jerome Charton, CEO commented, “We’re thrilled to welcome Ascenian’s team, bolstering our efforts at an exciting time for the company. The acquisition of Ascenian marks a significant step forward in Clinigen’s strategic transformation. By integrating Ascenian’s market access expertise we are strengthening our offering to our pharma and biotech partners, accelerating patient access to critical treatments and solidifying Clinigen’s position as a life sciences leader.”

Michael Epstein, co-Founder and Head of Commercial Strategy at Ascenian commented, “We started Ascenian to deliver groundbreaking treatments across the world as quickly as possible to the patients that need them most. Clinigen are a perfect fit for the next stage of our journey and feel like the natural home for us. We look forward to working together to deliver pioneering therapies.”

Dr Susanne Michel, co-Founder and Head of Health Technology Assessment (HTA) and Evidence at Ascenian commented, “This move facilitates a greater focus on market access services enabling us to support more patients in Europe and across the world, we can’t wait to join the Clinigen team.”

Through the acquisition, Clinigen will have access to Ascenian’s high calibre expertise through its Professional Learning Network (PLN). This consists of former policy makers, payers, HTA agency officials, clinical trial experts, and methodologists. The team execute projects across the globe including US, Japan, Europe, Brazil, and Canada, with new geographies and expertise domains added regularly.

Contact details

C: Isabel Paret, Fight or Flight

E: :


Notes to Editors

About Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients​ in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries and provides access in more than 130 countries every year.

For more information on Clinigen, please visit

About Ascenian, a Clinigen Company

Ascenian is a consulting company with a differentiated platform focused on pricing and market access. The company focuses on market access strategy for new pharmaceuticals, biotechnologies, diagnostics, preventive approaches and digital health technologies, with the goal of optimising decision planning to accelerate patient access to health innovations.

Ascenian delivers decision planning solutions in evidence generation, positioning, funding and care pathway analysis, pricing, forecasting negotiation, and continuous value demonstration, to ensure access to affordable innovations for patients, caregivers and health systems.

For more information on Ascenian please visit